ÉSTERES DE ÁCIDO FUMÁRICO - UMA OPÇÃO TERAPÊUTICA NA PSORÍASE EM PLACAS

Leonor Lopes; Ana Isabel Gouveia; Paulo Leal Filipe

doi:10.29021/spdv.73.3.458

Leonor Lopes Interna do Internato complementar de Dermatologia da Clínica Universitária de Dermatologia/ Resident of Dermatology and Venereology of Lisbon University
Ana Isabel Gouveia Interna do Internato complementar de Dermatologia da Clínica Universitária de Dermatologia/ Resident of Dermatology and Venereology of Lisbon University
Paulo Leal Filipe Professor de Dermatologia e Venereologia da Clínica Universitária de Dermatologia/Professor of Dermatology and Venereology of Lisbon University

DOI: https://doi.org/10.29021/spdv.73.3.458

Palavras-chave: Fumaratos, Psoríase

Resumo

Os ésteres de ácido fumárico estão licenciados para o tratamento sistémico da psoríase, na Alemanha, desde 1994. Estes derivados do fumarato constituem uma terapêutica eficaz, segura e económica quando comparada com outras terapêuticas sistémicas utilizadas no tratamento da psoríase moderada a grave. Considera-se que este fármaco tem um grande potencial, não só para o tratamento da psoríase em placas, como também para outras doenças dermatológicas menos frequentes. Este artigo tem como objetivo efetuar uma revisão sobre mecanismos de acção, indicações e contra-indicações para esta terapêutica.

Downloads

Não há dados estatísticos.

Referências

Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med. 2005;

:43-48.

Meissner M, Valesky EM, Kippenberger S, Kaufmann R. Dimethyl fumarate - only an anti-psoriatic medication? J Dtsch Dermatol Ges. 2012; 10:793-801.

Hoefnagel JJ, Thio HB, Willemze R, Bavinck JNB. Therapeutics Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol. 2003; 149(2):363-9.

Moharregh-Khiabani D, Linker R, Gold R, Stangel M. Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol. 2009; 7:60-4.

Breuer K, Gutzmer R, Völker B, Kapp A, Werfel T. Therapy of noninfectious granulomatous skin diseases with fumaric acid esters. Br J Dermatol. 2005; 152:1290-5.

Walker F, Adamczyk A, Kellerer C, Belge K, Brück J, Berner T, et al. Fumaderm® in daily practice for psoriasis:

dosing, efficacy and quality of life. Br J Dermatol. 2014; 171:1197-1205.

Boer A, Roll A, Reich K. Use of fumaric acid esters in psoriasis. Indian J Dermatol Venereol Leprol. 2007; 73:133.

Wain EM, Darling MI, Pleass RD, Barker JN, Smith CH. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. Br J Dermatol. 2010; 162):427-34.

Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, et al. Antipsoriasis effect of fumaric acid

derivatives: Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol. 1994; 30:977-81.

Fallah Arani S, Neumann H, Hop WC, Thio HB. Fumantes vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. Br J Dermatol. 2011; 164:855-61.

Brewer L, Rogers S. Fumaric acid esters in the management of severe psoriasis. Clin Exper Dermatol. 2007;

:246-9.

Thio HB, van der Schroeff JG, Nugteren-Huying WM, Vermeer BJ. Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm®) in psoriasis. J Eur Acad Dermatol Venerol. 1995; 4:35-40.

Carboni I, De Felice C, De Simoni I, Soda R, Chimenti S. Fumaric acid esters in the treatment of psoriasis: an

Italian experience. J Dermatol Treat. 2004; 15:23-6.

Systemic treatment of psoriasis vulgaris. European Dermatology forum (2012). [consultado 9 Junho de 2015]. Disponível em: http://www.google.pt/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=0CCUQFjABahU

KEwjQiuu5m43GAhVLQBQKHWR2ADo&url=http%3A%2F%2Fwww.euroderm.org%2Fedf%2Findex.php%2Fedf-

-guidelines%2Fcategory%2F5-guidelines-miscellaneous%3Fdownload%3D32%3Aguideline-psoriasis&ei=-

-Gp8VdCuEMuAUeTsgdAD&usg=AFQjCNHLF9cNLXl11ltPT51TyncHKtkoyQ&sig2=zOawpxuIQN4E77zg-

-Zf6CA&bvm=bv.95515949,d.d24.

Balasubramaniam P, Stevenson O, Berth-Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol. 2004; 150:741-6.

Schmitt J, Zhang Z, Wozel G, Meurer M and Kirch W. Efficacy and tolerability of biologic and non biologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2008; 159:513-26.

Fumaderm®: what is the evidence for its efficacy and safety in treating psoriasis? UK Medicines Information

(UKMi) pharmacists for NHS healthcare professionals. Oct 2013. [consultado 9 Junho de 2015]. Disponível

em: http://www.google.pt/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=0CCUQFjABahUKEwiWmZL7

ozGAhUDOxQKHW1tAAw&url=http%3A%2F%2Fwww.medicinesresources.nhs.uk%2Fupload%2Fdocuments%2

FEvidence%2FMedicines%2520Q%2520%26%2520A%2FNW%2520QA246.2%2520Fumaderm%2520for%252

psoriasis.doc&ei=7jN8VZbqCIP2UO3agWA&usg=AFQjCNHH9fr6tud5d8FHdnhKk8mgUcytJw&sig2=sLTRg2

BH0H2wHFyYYbmUSA&bvm=bv.95515949,d.ZGU.

Ormerod AD, Mrowietz U. Fumaric acid esters, their place in the treatment of psoriasis. Br J Dermatol. 2004;

:630-2.

Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. Br J Dermatol. 1998; 138:456-60.

Harries MJ, Chalmers RJ, Griffiths CE. Fumaric acid esters for severe psoriasis: a retrospective review of 58

cases. Br J Dermatol. 2005; 153:549-51.

Van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattles MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med. 2013;368:1658-9.

Gerdes S, Domm S, Mrowietz U. Long-term treatment with fumaric acid esters in an 11-year old male child with psoriasis. Dermatology. 2011; 222:198-200.

Balak DM, Oostveen AM, Bousema MT, Venema AW, Arnold WP, Seyger MM, et al. Effectiveness and safety of

fumaric acid esters in children with psoriasis: a retrospective analysis of 14 patients from the Netherlands. Br J

Dermatol.2013; 168:1343-7.

Eberle FC, Ghoreschi K, Hertl M. Fumaric acid esters in severe ulcerative necrobiosis lipoidica: a case report

and evaluation of current therapies. Acta Derm Venereol. 2010; 90104-6.

Venten I, Hess N, Hirschmüller A, Altmeyer P, Brockmeyer N. Treatment of therapy - resistant alopecia aerate with fumaric acid esters. Eur J Med Res. 2006; 11:300-5.

Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis:

an assessment of the benefits and risks. Br J Dermatol. 2005; 152:597-615.

Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess. 2000; 4:1-125.

NIHR Horizon Scanning Centre. Dimethyl fumarate for plaque psoriasis. 2013 [consultado 9 Junho de 2015].

Disponível: http://www.hsc.nihr.ac.uk.

Thaci D, Weisenseel P, Phillipp S, Rosenbach T, Rotterdam S, Augustin M, et al. Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions – a retrospective evaluation (FACTS). J Dtsch Dermatol Ges. 2013; 11:429-36.

Fika Z, Williams RE, Williamson DJ. Fumaric acid esters in psoriasis. Br J Dermatol. 2006; 154:567-8.